Gliomas can be characterized by several pathological molecular changes, including telomerase reverse transcriptase promoter mutations, isocitrate dehydrogenase mutations, methylguanine methyltransferase promoter methylation, 1p/19q codeletion and alpha thalassemia retardation syndrome X-linked (ATRX) mutations [2]. The gene discussed is IDH3A; the disease is central nervous system cancer.